Skip to content

Endpoint Enabling Study in Cyclin-dependent kinase-like 5 Deficiency Disorder (CDD)

Epilepsy

The study is designed to identify the best outcome measures in assessing their suitability and the adaptability across a variety of countries and languages for future international clinical
trials for patients with CDD.

null

Participation Requirements

  • Sex:

    Male, Female, Intersex

  • Eligible Ages:

    0 to 17

Participation Criteria

Inclusion Criteria:
Patients ages newborn to 17 years old with documented diagnosis of CDKL5 deficiency
Exclusion Criteria:
Any condition that, in the opinion of the investigator, would put the patient at
undue risk or make it unsafe for the patient to participate

Study Location

University of Calgary
University of Calgary
Calgary, Alberta
Canada

Contact Study Team

Study Sponsored By
University of Calgary
Participants Required
More Information
Study ID: REB22-0797